Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 07 - 29    symbols : VTRS    save search

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Published: 2021-07-29 (Crawled : 04:00) - prnewswire.com
VTRS | News A | $11.37 0.09% 1.2M twitter stocktwits trandingview |
Health Technology
| | O: 2.88% H: 0.27% C: -2.39%

diabetes treatment injection insulin approval biosimilar glargine
Gainers vs Losers
55% 45%

Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M twitter stocktwits trandingview |
Consumer Services

CZOO | $11.04 121.24% 9.6M twitter stocktwits trandingview |

BOF | $2.05 75.21% 78M twitter stocktwits trandingview |

AMST | $3.2 60.0% 63M twitter stocktwits trandingview |
Technology Services

LICN | $0.8592 53.43% 13M twitter stocktwits trandingview |

WIMI | $1.05 44.75% 13M twitter stocktwits trandingview |
Technology Services

TROO | $1.51 38.53% 5.6M twitter stocktwits trandingview |
Manufacturing

MULN | News | $3.7 35.53% 6.4M twitter stocktwits trandingview |
Information

RILY | $27.91 28.5% 8.9M twitter stocktwits trandingview |
Finance

WHLM | $6.43 26.58% 580K twitter stocktwits trandingview |
Commercial Services


Your saved searches
Save your searches and get alerts when important news are released.